RE: Company update / plans for the future24 Aug 2022 21:39
Tommy
Everything you say is true on what Synairgen achieved. It only leaves two issues they missed out on. The first was not linking with a biomarker on retained bolld samples in trial participants via biobanking. The second is having the means to have a single production batch annually for orphan drug prescription use at a lower price than say £2,000 a dose. If it was half that cost it would be utilised for a wider healthcare market and would get a good take up despite having to pay for the biomarker test or screening for it amongst a larger group of patients. Both skill sets are embedded at Southampton a former home of managing the Health Technology Assessment programme. The best skills sat on Synairgen's doorstep and some of us thought they may have used the talent that was around them. Instead it was over confidence and failing to guard attention to detail that scored against them and that includes that have dedicated years to that medication. Synairgen has staff and its leaders scarred by what happened.
I still have a few shares Tommy, but 7,000 I did have and sold as losses are now fully recovered with gains elsewhere. I am still recovering more but I feel better capturing gains and partially moving on. Everyone who invested in Synairgen backed good science and they backed a great centre to deliver it. Nobody should blame themselves for what happened as we were not part of the inside story and they really believed they had the bases covered. Anyone forecasting they knew it would fail have no facts to back it up. For those holding on, I hope you have more resources and are winning elsewhere as you wait for results here. It is important to think what you write on these boards as to whether it helps readers or not and if it doesn't do not write it. I hope what I have said here helps some of you. Stay well and kind regards Tony